Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients With Relapsing Remitting Multiple Sclerosis (MS) Transitioning From Current Subcutaneous Interferon Therapy to Peginterferon Beta 1a (PLEGRIDY™)

NCT03177083 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT03177083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03177083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients With Relapsing Remitting Multiple Sclerosis (MS) Transitioning From Current Subcutaneous Interferon Therapy to Peginterferon Beta 1a (PLEGRIDY™)
Lead sponsor
Biogen
Phase
Phase 4
Overall status
Completed
Start date
January 30, 2017
Completion date
October 26, 2020
Enrollment
80 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing remitting multiple sclerosis